IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition.
|
press release announcing its financial results for the quarter
ended December 31, 2016. A copy of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
hereto, shall not be deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such
filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release, dated March 7, 2017.
|
|
About IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA). IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Recent Trading Information
IMMUNE DESIGN CORP. (NASDAQ:IMDZ) closed its last trading session up +0.10 at 5.10 with 52,188 shares trading hands.
